Introduction to remission in ADHD: Raising the bar

Clinical Therapeutics

Volumn 28, Issue 11, 2006, Pages 1879-1881

  Steele, Margaret ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE; PLACEBO;

ARTICLE; ATTENTION DEFICIT DISORDER; CHILD PSYCHIATRY; DISTRESS SYNDROME; DRUG FORMULATION; FUNCTIONAL DISEASE; GOAL ATTAINMENT; HUMAN; LONG TERM EXPOSURE; MEDICAL LITERATURE; MEDICAL RESEARCH; MENTAL DISEASE; ONSET AGE; PREVALENCE; REMISSION; WELLBEING;

EID: 33845950915     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.11.005     Document Type: Article

References (31)

1. Demyttenaere K., Bruffaerts R., Posada-Villa J., et al., WHO World Mental Health Survey Consortium. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA 291 (2004) 2581-2590
2. Paykel E.S., Ramana R., Cooper Z., et al. Residual symptoms after partial remission: An important outcome in depression. Psychol Med. 25 (1995) 1171-1180
3. Miller I.W., Keitner G.I., Schatzberg A.F., et al. The treatment of chronic depression, part 3: Psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry. 59 (1998) 608-619
4. Simon G.E., Revicki D., Heiligenstein J., et al. Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry 22 (2000) 153-162
5. Wolraich M.L., Hannah J.N., Baumgaertel A., and Feurer I.D. Examination of DSM-IV criteria for attention deficit/hyperactivity disorder in a county-wide sample. Dev Behav Pediatr. 19 (1998) 162-168
6. Barbaresi W., Katusic S., Colligan R., et al. How common is attention-deficit/hyperactivity disorder? Towards resolution of the controversy: Results from a population-based study. Acta Paediatr Suppl. 93 (2004) 55-59
7. Barkley R.A., Fischer M., Edelbrock C.S., and Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 29 (1990) 546-557
8. Weiss G., Hechtman L., Milroy T., and Perlman T. Psychiatric status of hyperactives as adults: A controlled prospective 15-year follow-up of 63 hyperactive children. J Am Acad Child Psychiatry 24 (1985) 211-220
9. Barkley R.A., Fischer M., Smallish L., and Fletcher K. Young adult outcome of hyperactive children: Adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry 45 (2006) 192-202
10. [published correction appears in J Abnorm Child Psychol. 2003;31:563]. Fischer M., Barkley R.A., Smallish L., and Fletcher K. Young adult follow-up of hyperactive children: Self-reported psychiatric disorders, comorbidity, and the role of childhood conduct problems and teen CD. J Abnorm Child Psychol. 30 (2002) 463-475
11. Satterfield J.H., and Schell A. A prospective study of hyperactive boys with conduct problems and normal boys: Adolescent and adult criminality. J Am Acad Child Adolesc Psychiatry 36 (1997) 1726-1735
12. Biederman J., Wilens T., Mick E., et al. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): Effects of ADHD and psychiatric comorbidity. Am J Psychiatry 152 (1995) 1652-1658
13. Mannuzza S., Klein R.G., Bessler A., et al. Educational and occupational outcome of hyperactive boys grown up. J Am Acad Child Adolesc Psychiatry 36 (1997) 1222-1227
14. Murphy K., and Barkley R.A. Attention deficit hyperactivity disorder adults: Comorbidities and adaptive impairments. Compr Psychiatry 37 (1996) 393-401
15. Mitchell E.A., Aman M.G., Turbott S.H., and Manku M. Clinical characteristics and serum essential fatty acid levels in hyperactive children. Clin Pediatr (Phila) 26 (1987) 406-411
16. Barkley R.A., Guevremont D.C., Anastopoulos A.D., et al. Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: A 3- to 5-year follow-up survey. Pediatrics 92 (1993) 212-218
17. Frank E., Prien R.F., Jarrett R.B., et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 48 (1991) 851-855
18. (Suppl). Kupfer D.J. Long-term treatment of depression. J Clin Psychiatry. 52 (1991) 28-34
19. Swanson J.M., Kraemer H.C., Hinshaw S.P., et al. Clinical relevance of the primary findings of the MTA: Success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 40 (2001) 168-179
20. MTA Cooperative Group (Multimodal Treatment Study of Children with ADHD). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56 (1999) 1073-1086
21. Matza L.S., Rentz A.M., Secnik K., et al. The link between health-related quality of life and clinical symptoms among children with attention deficit hyperactivity disorder. J Dev Behav Pediatr. 25 (2004) 166-174
22. Swanson J.M., Wigal S.B., Wigal T., et al., COMACS Study Group. A comparison of once-daily extended release methylphenidate formulations in children with attention-deficit/ hyperactivity disorder in the laboratory school (the COMACS Study). Pediatrics 113 (2004) e206-e216
23. Hechtman L., Abikoff H., Klein R.G., et al. Academic achievement and emotional status of children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry 43 (2004) 812-819
24. Swanson J., Gupta S., Lam A., et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: Proof-of-concept and proofof-product studies. Arch Gen Psychiatry. 60 (2003) 204-211
25. Biederman J. Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: Findings from a longitudinal follow-up of youths with and without ADHD. J Clin Psychiatry 64 Suppl 11 (2003) 3-8
26. Wilens T.E., Faraone S.V., Biederman J., and Gunawardene S. Does stimulant therapy of attention-deficit/hyper activity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 111 (2003) 179-185
27. Steele M., Weiss M., Swanson J., et al. A randomized, controlled effectiveness trial of OROS-methylphenidate com pared to usual care with immediaterelease methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol. 13 (2006) e50-e62
28. Lage M., and Hwang P. Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment. J Child Adolesc Psychopharmacol. 14 (2004) 575-581
29. Cox D.J., Merkel R.L., Penberthy J.K., et al. Impact of methylphenidate delivery profiles on driving perfor mance of adolescents with attentiondeficit/hyperactivity disorder: A pilot study. J Am Acad Child Adolesc Psychiatry 43 (2004) 269-275
30. Washington, DC. Abstract NR452. Cox D., Humphrey J., Merkel R., et al. Once-daily OROS MPH effects on real-life driving in adolescents with ADHD. Presented at: New Research Abstracts, Annual Meeting of the American Psychiatric Association (May 1-6, 2004)
31. Stein M.A., Sarampote C.S., Waldman I.D., et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 112 (2003) e404